Telix Pharmaceuticals Limited
TLX
$10.68
-$0.07-0.61%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 206.72M | 206.72M | 195.18M | 195.18M | 138.47M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 206.72M | 206.72M | 195.18M | 195.18M | 138.47M |
| Cost of Revenue | 110.68M | 110.68M | 100.29M | 100.29M | 53.11M |
| Gross Profit | 96.04M | 96.04M | 94.89M | 94.89M | 85.36M |
| SG&A Expenses | 47.93M | 47.93M | 48.35M | 48.35M | 35.87M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -745.50K | -745.50K | 122.50K | 122.50K | 161.00K |
| Total Operating Expenses | 202.70M | 202.70M | 189.55M | 189.55M | 125.39M |
| Operating Income | 4.02M | 4.02M | 5.63M | 5.63M | 13.08M |
| Income Before Tax | -215.00K | -215.00K | -2.42M | -2.42M | 7.52M |
| Income Tax Expenses | 2.20M | 2.20M | -1.27M | -1.27M | 474.00K |
| Earnings from Continuing Operations | -2.42M | -2.42M | -1.15M | -1.15M | 7.05M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.42M | -2.42M | -1.15M | -1.15M | 7.05M |
| EBIT | 4.02M | 4.02M | 5.63M | 5.63M | 13.08M |
| EBITDA | 7.09M | 7.09M | 9.14M | 9.14M | 13.74M |
| EPS Basic | -0.01 | -0.01 | 0.00 | 0.00 | 0.04 |
| Normalized Basic EPS | -0.01 | -0.01 | 0.00 | 0.00 | 0.05 |
| EPS Diluted | -0.01 | -0.01 | 0.00 | 0.00 | 0.04 |
| Normalized Diluted EPS | -0.01 | -0.01 | 0.00 | 0.00 | 0.04 |
| Average Basic Shares Outstanding | 338.56M | 338.56M | 337.20M | 337.20M | 171.44M |
| Average Diluted Shares Outstanding | 338.56M | 338.56M | 337.20M | 337.20M | 182.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |